STOCK TITAN

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) announces participation in investor conferences. The company will be presenting at the Stifel Healthcare Conference on November 14, 2023, and at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023. Live webcasts and replays will be available on the company's website.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

  • Stifel Healthcare Conference
    Tuesday, November 14, 2023 at 3:00 p.m. ET (Fireside Chat)
  • Piper Sandler 35th Annual Healthcare Conference
    Thursday November 30, 2023 at 11:00 a.m. ET (Fireside Chat)

A live webcast of each presentation will be available by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for 90 days following each presentation.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir (formerly known as FTX-6058), a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608


FAQ

What is the ticker symbol of Fulcrum Therapeutics, Inc.?

The ticker symbol of Fulcrum Therapeutics, Inc. is FULC.

When will Fulcrum Therapeutics, Inc. be presenting at the Stifel Healthcare Conference?

Fulcrum Therapeutics, Inc. will be presenting at the Stifel Healthcare Conference on November 14, 2023 at 3:00 p.m. ET.

Where can I access the live webcast of Fulcrum Therapeutics, Inc.'s presentations?

The live webcast of each presentation will be available on Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations.

How long will the replays of the webcasts be available for viewing?

The replays of the webcasts will be available on Fulcrum Therapeutics' website for 90 days following each presentation.

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

FULC Rankings

FULC Latest News

FULC Stock Data

484.49M
38.46M
1.38%
99.44%
3.65%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About FULC

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng